ATE68977T1 - Pharmazeutisch aktive konjugate mit spezifitaet fuer die bindung an koerpergewebe. - Google Patents

Pharmazeutisch aktive konjugate mit spezifitaet fuer die bindung an koerpergewebe.

Info

Publication number
ATE68977T1
ATE68977T1 AT87907789T AT87907789T ATE68977T1 AT E68977 T1 ATE68977 T1 AT E68977T1 AT 87907789 T AT87907789 T AT 87907789T AT 87907789 T AT87907789 T AT 87907789T AT E68977 T1 ATE68977 T1 AT E68977T1
Authority
AT
Austria
Prior art keywords
pharmaceutically active
body tissue
pct
binding
active conjugates
Prior art date
Application number
AT87907789T
Other languages
English (en)
Inventor
Robert Albert Brown
Original Assignee
Central Blood Lab Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Central Blood Lab Authority filed Critical Central Blood Lab Authority
Application granted granted Critical
Publication of ATE68977T1 publication Critical patent/ATE68977T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6435—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a connective tissue peptide, e.g. collagen, fibronectin or gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153—Streptokinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
AT87907789T 1986-11-27 1987-11-27 Pharmazeutisch aktive konjugate mit spezifitaet fuer die bindung an koerpergewebe. ATE68977T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB868628398A GB8628398D0 (en) 1986-11-27 1986-11-27 Pharmaceutically-active conjugates
PCT/GB1987/000854 WO1988003810A1 (en) 1986-11-27 1987-11-27 Pharmaceutically active conjugates having improved body tissue binding specificity
EP87907789A EP0333740B1 (de) 1986-11-27 1987-11-27 Pharmazeutisch aktive konjugate mit spezifität für die bindung an körpergewebe

Publications (1)

Publication Number Publication Date
ATE68977T1 true ATE68977T1 (de) 1991-11-15

Family

ID=10608055

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87907789T ATE68977T1 (de) 1986-11-27 1987-11-27 Pharmazeutisch aktive konjugate mit spezifitaet fuer die bindung an koerpergewebe.

Country Status (10)

Country Link
US (1) US5151412A (de)
EP (1) EP0333740B1 (de)
JP (1) JP2721830B2 (de)
AT (1) ATE68977T1 (de)
AU (1) AU610104B2 (de)
DE (1) DE3774279D1 (de)
DK (1) DK168693B1 (de)
GB (1) GB8628398D0 (de)
NO (1) NO177526C (de)
WO (1) WO1988003810A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0340573A3 (de) * 1988-04-30 1990-05-30 BASF Aktiengesellschaft Neue Proteine, ihre Herstellung und Verwendung
US4892826A (en) * 1988-10-11 1990-01-09 Abbott Laboratories Process for the preparation of urokinase derivatives
US5654267A (en) * 1988-12-20 1997-08-05 La Jolla Cancer Research Center Cooperative combinations of ligands contained within a matrix
FI912858A0 (fi) * 1988-12-20 1991-06-13 Jolla Cancer Res Found Polypeptidpolymerkonjugat aktiva vid botande av saor.
EP0429663A1 (de) * 1989-06-13 1991-06-05 Nippon Soda Co., Ltd. Der menschlichen prourokinase ähnliche polypeptide und verfahren zu deren herstellung
US5013726A (en) * 1989-09-12 1991-05-07 Ivy Jeffery W External analgesic lotion containing active ingredients of methyl salicylate and camphor and menthol and method of making such lotion
US5124320A (en) * 1989-09-12 1992-06-23 Ivy Jeffery W An external analgesic lotion containing active ingredients of camphor and menthol and method of making such lotion
GB9023149D0 (en) * 1990-10-24 1990-12-05 British Bio Technology Proteins and nucleic acids
GB9101183D0 (en) * 1991-01-18 1991-02-27 Univ London Depot formulations
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
DK0598719T3 (da) * 1991-07-31 1999-06-14 Antex Biolog Inc Receptorkonjugater til destinering af lægemidler og andre midler
JP2829405B2 (ja) * 1991-10-14 1998-11-25 寳酒造株式会社 機能性ポリペプチド
CN1091315A (zh) * 1992-10-08 1994-08-31 E·R·斯奎布父子公司 血纤维蛋白封闭剂组合物及其使用方法
US5591719A (en) * 1992-12-10 1997-01-07 Regents Of The University Of Minnesota Method for treating acute and chronic inflammatory disorders using polypeptides with fibronectin activity
DE4242736A1 (de) * 1992-12-17 1994-06-23 Behringwerke Ag Synthetische Peptide, Antikörper dagegen und ihre Verwendung
WO1994016085A2 (en) * 1992-12-30 1994-07-21 Zymogenetics, Inc. Hybrid proteins having cross-linking and tissue-binding activities
WO1994017097A1 (en) * 1993-01-19 1994-08-04 Regents Of The University Of Minnesota Synthetic fibronectin fragments as inhibitors of retroviral infections
US5821074A (en) * 1993-12-21 1998-10-13 Abbott Laboratories Method and compositions for enhancing aminolevulinic acid dehydratase assay
CA2253204A1 (en) * 1996-05-03 1997-11-13 Roger S. Cubicciotti Prodrug compositions and drug delivery methods using synthetic receptors
CA2315702A1 (en) * 1997-12-24 1999-07-08 Immunex Corporation V196 dna and polypeptides
DE69932247T2 (de) * 1998-08-21 2007-05-31 Immunex Corp., Thousand Oaks Menschliches il-1 epsilon dna und polypeptide
IN190822B (de) * 1998-12-24 2003-08-23 Council Scient Ind Res
US7553810B2 (en) 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US7678767B2 (en) * 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
EP2064300A4 (de) * 2006-09-20 2013-05-22 Pneumrx Inc Gewebehaftzusammensetzungen und verfahren dafür

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541435A (en) * 1975-02-04 1979-02-28 Searle & Co Immunological materials
GB2116979B (en) * 1982-02-25 1985-05-15 Ward Page Faulk Conjugates of proteins with anti-tumour agents
AR241654A1 (es) * 1982-05-05 1992-10-30 Genentech Inc Procedimiento para producir activador de plasminogeno de tejido humano.
US4589881A (en) * 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
JPS59134732A (ja) * 1983-01-21 1984-08-02 Green Cross Corp:The フイブロネクチン・生理活性物質複合体の製造法
JPS60226819A (ja) * 1984-04-25 1985-11-12 Green Cross Corp:The フイブロネクチン複合体
AU583854B2 (en) * 1984-09-13 1989-05-11 Cytogen Corporation Antibody therapeutic agent conjugates
US4587122A (en) * 1985-04-23 1986-05-06 The Green Cross Corporation Fibronectin-dextran-drug complex and method of preparation thereof

Also Published As

Publication number Publication date
EP0333740B1 (de) 1991-10-30
DK168693B1 (da) 1994-05-24
DE3774279D1 (de) 1991-12-05
NO177526B (no) 1995-06-26
DK420988A (da) 1988-07-27
AU8277387A (en) 1988-06-16
DK420988D0 (da) 1988-07-27
NO883306L (no) 1988-07-26
JP2721830B2 (ja) 1998-03-04
JPH02501305A (ja) 1990-05-10
AU610104B2 (en) 1991-05-16
NO883306D0 (no) 1988-07-26
US5151412A (en) 1992-09-29
EP0333740A1 (de) 1989-09-27
GB8628398D0 (en) 1986-12-31
WO1988003810A1 (en) 1988-06-02
NO177526C (no) 1995-10-04

Similar Documents

Publication Publication Date Title
DE3774279D1 (de) Pharmazeutisch aktive konjugate mit spezifitaet fuer die bindung an koerpergewebe.
ATE324119T1 (de) Verwendung von saccharid-konjugaten
ES2227527T3 (es) Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada.
ATE342728T1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
CY1112845T1 (el) Παραγωγα της 1-δεοξυ-γαλακτονογιριμυκινης και η χρηση τους στη θεραπεια αθροιστικων λυσοσωμικων ασθενειων μεσω ενισχυσης της λυσοσωμικης α-γαλακτοσιδασης α
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
EP0786995A4 (de)
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
NO901986D0 (no) Nytt antistoff-leveringssystem for biologisk respons-modifiserende midler.
PL335140A1 (en) Therapeutic agent for treating lymphatic system carcinomas
ES2164914T3 (es) Medicamentos de inmunoterapia que contienen anticuerpos que detectan especificamente el antigeno mhcii del paciente a tratar.
EP1003494A4 (de) (d)-METHADON, NICHT-OPIATES SCHMERZMITTEL
DE3781652D1 (de) Zubereitung, geeignet fuer die behandlung von darmstoerungen.
HUP9802206A1 (hu) Thalidomid intravénás adagolási formája immunológiai megbetegedések gyógyításához
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
DE69033990D1 (de) Glykoprotein-Hormonrezeptor-Moleküle
TR199802200A2 (xx) S�lfonamid s�bstit�e edilmi� benzopiran t�revleri, �retilme y�ntemi.
MY124071A (en) Treatment of viral disease in swine
DE60132436D1 (de) Retinolsäure-rezeptor beta-2 und gentherapievektoren für die behandlung von neurologischen erkrankungen
ATE317021T1 (de) Antisense modulierung von lfa-3
DE59510674D1 (de) Verwendung von selegilin zur behandlung von epileptischen erkrankungen
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE329600T1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.